About GSK in Pakistan

GlaxoSmithKline Pakistan Limited was created January 1st, 2001 through the merger of SmithKline and French of Pakistan Limited, Beecham Pakistan (Private) Limited and Glaxo Wellcome (Pakistan) Limited- standing today as the largest pharmaceutical company in Pakistan. As an industry leader we are committed to our mission of providing patients quality products to help improve their lives. Take a look through our About Us section to learn more.

Our Mission
GlaxoSmithKline one of the world's leading research-based pharmaceutical and healthcare companies is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Our Values
GSK values are deeply embedded in every function, across the globe. Strategic development, operations, and customer engagement are based on our values of

As a leading international pharmaceutical company we make a real difference to global healthcare and specifically to the developing world. We believe this is both an ethical imperative and key to business success. Companies that respond sensitively and with commitment by changing their business practices to address such challenges will be the leaders of the future. GSK Pakistan operates mainly in two industry segments: Pharmaceuticals (prescription drugs and vaccines) and consumer healthcare (over-the-counter- medicines, oral care and nutritional care). GSK Pakistan leads the industry in value, volume and prescription market shares, and we are committed to our mission of providing patients quality products to help improve the quality of their lives. Some of our leading pharmaceutical brands include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and renowned consumer healthcare brands, which include Panadol, Horlicks, Aquafresh, Macleans and ENO. Leading Pharmaceutical Brands

Renowned

Consumer

Healthcare

Brands

Anti-infectives

Analgesics

Anti-Virals

Central Nervous System

Respiratory

Vision statement
GlaxoSmithKline is committed to discovering and developing new medicines and vaccines
R&D Themes under the GSK strategy:
Best Science: Focusing our efforts in areas where the science is most fertile to discover new medicines of value to both patients and payers Re-personalise R&D: Creating small teams, where an individual can have a personal impact and be intimate with the project Diversify through Externalisation: We will scout the world to find new science and ideas Focus on Return on Investment: We will spend less on buildings and infrastructure and more on our growing late stage pipeline

The Research Process:

Global

Manufacturing
Mission

and

Supply

Global Manufacturing and Supply (GMS) is a very strong global manufacturing network in GlaxoSmithKline. There are 79 manufacturing sites spread over 33 countries across the globe, supported by central and global groups. GMS is focused on the fundamentals of manufacturing, quality, safety and continuous improvements.

By adopting leading edge practices, developing our people and focussing on performance, we will ensure GSK benefits from A secure source of supply of high quality products Compliance with regulatory requirements and customer expectations Best in class cost

Strategy
To be a highly competent business at introducing new products To be a sustainable, low cost manufacturer & supplier to allow us to compete in all markets Support the commercial ambition of GSK

GSK in the Community

GlaxoSmithKline (GSK) strives to be a valued corporate citizen no matter where it does business. We have always shown strong commitment and support for public health and awareness initiatives and championed many social causes. At GSK, we know that part of being a successful and sustainable business is fulfilling our social responsibilities, making our company more responsive, more flexible and more open to societys expectations. We are working towards improving access to our medicines, enhancing research opportunities for neglected tropical diseases, raising the ethical standards for conducting our research and business activities, and being more open and transparent in the way we run our business. We are adapting our business model to adopt a more open approach to R&D for diseases of the developing world. GSK has put many of its important resources including a pool of patents, research know-how and technology assets into an open knowledge pool. Researchers outside of GSK can now use this information, which will hopefully stimulate cutting-edge research on medicines for neglected diseases, including malaria. The knowledge pool is now being administered by the not-for-profit BIO Ventures for Global Health. As part of this initiative, GSK announced in January 2010, the establishment of the first ever Open Lab to act as an engine room of scientific innovation for neglected tropical diseases. GSK has created capacity for up to 60 scientists from around the world to have access to the Open Lab, which will be based at the companys research centre at the Tres Cantos Campus, Spain. In the Open Lab, scientists will be encouraged to tap into the expertise, knowledge and infrastructure of the company, while pursuing their own projects as part of an integrated drug discovery team. In June 2010 GSK was ranked top in the Access to Medicine Index for the second successive time. The Access to Medicine Index is a ranking of worlds largest pharmaceutical companies on their efforts to increase access to medicine for societies in need. GSK also announced the formation of a new operating unit dedicated to expanding access to medicines for people living in Least Developed Countries (LDCs) in 2010. GSK believes in working as partners with under-served communities in the developed and developing

world supporting programmes that are innovative, sustainable and bring real benefit to these communities. Our programmes are organised into global, regional and local activities.